Sweden. Elekta AB

The investment loan of EUR 50 million to Elekta AB will support the financing of its research and development budget for the period of 2022 – 2025. The loan will focus on increased R&D spending in Sweden and Finland, where Elekta has a strong R&D presence, and will allow the company to continue to innovate and advance cancer care.

Elekta’s R&D efforts are strategically focused on precision, productivity, resource optimisation, and integrated informatics to advance cancer care. With a growing emphasis on the utilization of artificial intelligence and machine learning, Elekta is committed to developing innovative devices and solutions that enhance the accuracy of diagnoses, optimize treatment selections, and improve patient outcomes.

NIB has supported Elekta’s R&D activities through two loans, amounting to GBP 180 million since 2017. The recent investment of EUR 50 million for Elekta’s R&D budget for 2022-2025 highlights the ongoing collaboration between the two entities.

The investment loan represents continuity in the long-term cooperation between NIB and Elekta, providing financing for the company’s R&D expenditures in Finland and Sweden during 2022-2025.

Medtech clusters are attractive hubs for creating knowledge and skill networks across companies, improving industry performance. Elekta’s expertise, in combination with collaborations with universities and other companies, contributes to sector-specific knowledge gains.

Elekta’s investment in research and development, as well as their focus on developing more efficient radiation treatment solutions, is expected to result in significant benefits for society. This encompasses a decrease in mortality and morbidity rates in oncologic diseases, as well as an increase in the number of healthy life-years through improved access to radiation therapy.

NIB has not identified any significant environmental issues connected to the R&D program.